Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on May 20, 2015 in Breast cancer | 0 comments

In a nutshell

The authors aimed to assess the results of a specific pre-operative chemotherapy.

Some background

Pre-operative chemotherapy is used to shrink the tumor before surgery. Abraxane and cyclophosphamide (Endoxan) are used as combined chemotherapy and referred to as ABC. 5-fluorouracil (Adrucil), epirubicin (Pharmorubicin) and cyclophosphamide are another combination treatment referred to as FEC. ABC has been confirmed as valuable chemotherapy due to its safety and overall survival rate.

To date, the effects of ABC used with FEC have not been well studied. 

Methods & findings

This article aimed to evaluate the safety of ABC and FEC administered three times per week as a pre-operative chemotherapy. 54 women with invasive breast cancer (the cancer can spread quickly) began this 8-week treatment. 17 of these were positive for human epidermal growth factor receptor 2 (HER2+) and 13 were negative for both HER2 and hormone receptors (the absence of estrogen or progesterone receptor proteins on the cancer cells). This is known as triple-negative breast cancer.

All women underwent surgery after this treatment.

Some adverse events (an unexpected health issue – may or may not be treatment related) were observed including mild anemia (low red blood cell count; only 15% of all women), rash (2% following ABC treatment only) and moderate fatigue (17%). After full treatment, however, mild nausea was the only major side effect (41%).

Overall, 37% of the women with breast cancer, including 62% of the women with triple negative cancer, achieved complete disappearance of the cancer.

The bottom line

The authors concluded that TRI-ABC and FEC is a safe pre-operative chemotherapy.

The fine print

This study included a small group of patients.

Published By :

Clinical Breast Cancer

Date :

Apr 01, 2015

Original Title :

The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-Fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial.

click here to get personalized updates